Quetiapine for schizophrenia (Q24247154)

Europe PubMed Central

title

Quetiapine for schizophrenia (English)

0 references

0 references

3

Narong Maneeton

0 references

Manit Srisurapanont

1

object named as

Manit Srisurapanont

0 references

Benchalak Maneeton

2

object named as

Benchalak Maneeton

0 references

author name string

Sudheer Lankappa

4

0 references

Rahul Gandhi

Cochrane Database of Systematic Reviews

5

0 references

publication date

19 April 2004

0 references

published in

0 references

cites work

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Previous treatment as a confounding variable in studies with novel antipsychotics: two cases of high dopamine-2 receptor occupancy with quetiapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Seroquel (ICI 204 636), a putative "atypical" antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

A rating scale for drug-induced akathisia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Should unpublished data be included in meta-analyses? Current convictions and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Risperidone versus other atypical antipsychotic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Seroquel: electrophysiological profile of a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Detection and management of comorbidity in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Rating the quality of evidence for clinical practice guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Risperidone versus typical antipsychotic medication for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Lithium for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

What are pragmatic trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Seroquel: biochemical profile of a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

21 January 2018

1 reference

12 December 2020

Medical-claims databases in the design of a health-outcomes comparison of quetiapine ('Seroquel') and usual-care antipsychotic medication

1 reference

12 December 2020

New generation antipsychotics for first episode schizophrenia

1 reference

12 December 2020

A comparison of bd and tid dose regimens of quetiapine (Seroquel) in the treatment of schizophrenia

1 reference

12 December 2020

Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol

1 reference

12 December 2020

Clozapine versus typical neuroleptic medication for schizophrenia

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group

1 reference

12 December 2020

Effects of 'Seroquel' (quetiapine) on platelet serotonin-2 binding in schizophrenia

1 reference

12 December 2020

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

1 reference

12 December 2020

ICI 204,636: a new atypical antipsychotic drug

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

Detecting skewness from summary information

1 reference

12 December 2020

A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia

1 reference

12 December 2020

Lithium for schizophrenia

1 reference

12 December 2020

Clozapine versus typical neuroleptic medication for schizophrenia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

7 January 2021

inferred from DOI database lookup

Olanzapine for schizophrenia.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000967.PUB2

7 January 2021